AC
NEUP

Armistice Capital’s Neuphoria Therapeutics NEUP Stock Holding History

Armistice Capital’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-132,750
Closed -$700K – 309
2024
Q3 		$700K Buy
132,750
+30,520
+30% +$242K 0.01% 180
2024
Q2 		$941K Buy
+102,230
New +$1.11M 0.01% 164

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's NEUP Position: Q4 2024 in Review

Armistice Capital sold out of Neuphoria Therapeutics (NEUP) in Q4 2024, closing a stake of 132,750 shares — an estimated $700K sold.

Armistice Capital first reported a position in NEUP in Q2 2024 and held it in 2 quarters. The position peaked at $941K in Q2 2024. 8 funds tracked by Wall St. Rank hold NEUP as of Q4 2024.

  • Armistice Capital reported no remaining Neuphoria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 132,750 Neuphoria Therapeutics shares in Q4 2024, an estimated $700K.
  • Armistice Capital first reported a position in Neuphoria Therapeutics in Q2 2024 and held it in 2 quarters.
  • Armistice Capital's Neuphoria Therapeutics position peaked at $941K in Q2 2024.
  • 8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.